Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 67,048

Document Document Title
WO/2021/068953A1
The present invention belongs to the field of medicinal chemistry and relates to a class of substituted tricyclic compounds as PRMT5 inhibitors and the use thereof. Specifically, the present invention provides a compound represented by f...  
WO/2021/066088A1
Provided is a compound represented by the following formula (1) and a pharmacologically acceptable salt, which have a regulatory activity for a histamine H4 receptor and are useful for the treatment and/or prevention of diseases or condi...  
WO/2021/064186A1
The present invention concerns novel pyridin-2(1H)one derivatives, their process of preparation and their use in therapeutics, in particular as agents for treating and/or preventing pain.  
WO/2021/067805A1
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...  
WO/2021/067772A1
Formulations of Compound 1 or a pharmaceutically acceptable salt thereof are described. Also disclosed are capsules having a dry blended powder comprising Compound 1 or a pharmaceutically acceptable salt thereof. The Compound 1 or a phar...  
WO/2021/064677A1
Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: Formula I.  
WO/2021/065980A1
Provided is a BET degrader. A BET degrader including a compound represented by formula (I) or a pharmaceutically acceptable salt thereof is used. (In the formula, L1 and L2 are the same or different and represent a low molecular ligand f...  
WO/2021/066578A1
The present invention relates to a compound derivative bearing a 6-7 bicyclic ring and a use thereof. The compound according to the present invention acts as a protein arginine methyltransferases 5 (PRMT5) inhibitor and thus can be advan...  
WO/2021/064590A1
Described herein are compounds of Formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are defined herein, their use as diacylglycerol acyltransferase 2 (DGAT2) inhibitors, pharmaceutical compositions containing such inhibitors and...  
WO/2021/066573A1
The present invention pertains to: a novel compound; and a use thereof in treating autoimmune diseases. A pharmaceutical composition for treating or preventing autoimmune diseases containing the novel compound of the present invention ca...  
WO/2021/063856A1
The present invention provides novel compounds having the general formula (I) wherein R1 to R6 are as described herein, compositions including the compounds and methods of using the compounds.  
WO/2021/067215A1
The present disclosure provides compounds represented by Formula (la): and the pharmaceutically acceptable salts thereof, wherein R1a, R1b, R1c, R2, R3, L, M and G are as defined as set forth in the specification. The present disclosure ...  
WO/2021/063821A1
The present invention covers pyrimidinedione derivatives of general formula (I) : (I), in which R1, R2, R4, R5 and X are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, ...  
WO/2021/064175A1
The present invention relates to a composition for use in preventing migration of cancer cells in a subject known or suspected to suffer from cancer, the composition comprising at least one metal complex having the structure (I), formula...  
WO/2021/064142A1
The present invention relates to a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof : formula (I) and to pharmac...  
WO/2021/067521A1
The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical composit...  
WO/2021/066559A1
N-(1H-imidazol-2-yl)benzamide compound of formula (I), or a pharmaceutically acceptable salt, a prodrug, a solvate, or a stereoisomer thereof which is a novel compound exhibiting excellent inhibitory activity against IRAK-4, can be used ...  
WO/2021/065492A1
Provided is an organic EL element which has high efficiency and high driving stability, while having low drive voltage. This organic EL element is characterized by having one or more light emitting layers between a positive electrode and...  
WO/2021/067657A1
Disclosed are compounds of Formula (I) or salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, 8, or 9, and pharmace...  
WO/2021/063207A1
Provided are a compound as shown in formula (I), which formula is as follows, and racemates, stereoisomers, tautomers, isotopic markers, solvates, polymorphs and oxynitrides of the compound, or a pharmaceutically acceptable salt thereof,...  
WO/2021/067266A1
Disclosed herein are pyrrolidinyl-based compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.  
WO/2021/067801A1
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or prodrug, and/or tautomer, and/or drug combination of the compound) that inhibit (e.g., antagoniz...  
WO/2021/067859A1
Provided herein is a compound of Formula (I), or pharmaceutically acceptable salt thereof, wherein R1, Y, X, and n are defined herein. Also provided herein are compositions comprising a compound of Formula (I) or pharmaceutically accepta...  
WO/2021/067374A1
The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 enzyme and are useful in the treatment of F GFR3-associated diseases such as cancer.  
WO/2021/067654A1
Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.  
WO/2021/056811A1
Disclosed are an imine salt derivative and a preparation method therefor, and a preparation method for nicotine. The preparation method for nicotine comprises the following steps: adding an imine salt derivative having a general formula ...  
WO/2021/058754A1
The invention provides a composition of matter which: • (i) consists of at least 90 % by weight of an atropisomer (2A) and 0-10 % by weight of an atropisomer of formula (2B); or • (ii) consists of at least 90 % by weight of an atropi...  
WO/2021/061644A1
The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions. In some embodiments, the compounds disclos...  
WO/2021/061053A1
There are provided new heterobifunctional agents designed to mediated formation of protein-protein dimers and promote ubiqutination of a protein of the dimer. Also provided are methods of synthesizing the agents, pharmaceutical formulati...  
WO/2021/057890A1
A class of compounds that have a pyrazine structure, specifically disclosed is a compound represented by formula (VII), isomers or pharmaceutically acceptable salts thereof, and an application thereof in the preparation of CRAC inhibitors.  
WO/2021/057853A1
Provided aza-quinoline compounds of Formula (I), pharmaceutical compositions comprising such compounds; and the use of such compounds for treating a disease or condition mediated by Enhancer of Zeste Homolog 2 (EZH2), Polycomb Repressive...  
WO/2021/057785A1
Disclosed is a compound represented by formula I, a stereoisomer, racemate, tautomer, isotopic label, prodrug thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising same, a preparation method t...  
WO/2021/057832A1
Privided is a KRAS mutant protein inhibitor, a composition containing the inhibitor and the use thereof.  
WO/2021/060948A1
The present invention relates to a novel method for preparation of efinaconazole in an ionic liquid medium, the method comprising: reacting 1-[[(2R,3S)-2-(2,4-difluorophenyl)-3-methyloxiranyl]methyl]- 1H-1,2,4-triazole, and 4-methylenepi...  
WO/2021/057782A1
Disclosed are a TAM family kinase /and Ron kinase inhibitor compound as shown in general formula (I), a pharmaceutically acceptable salt, an ester, a stereoisomer and a tautomer thereof, a pharmaceutical composition and a pharmaceutical ...  
WO/2021/059017A1
Provided is a heterocyclic compound that can have an antagonistic action on an NMD A receptor containing the NR2B subunit and that is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine...  
WO/2021/059136A1
Compounds of the general formula (I), or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.  
WO/2021/057872A1
Disclosed are a compound represented by general formula (I) or a pharmaceutically acceptable salt, stereoisomer, ester, prodrug, solvate and deuterated compound thereof, a composition which comprises the compound represented by general f...  
WO/2021/061695A1
Methods of treating EGFR mutant-related cancers with a combination of an EGFR inhibitor of Formula (I) and the CDK4/6 inhibitor of Formula (II) and use of combinations of these compounds in the manufacture of medicaments for the treatmen...  
WO/2021/062245A1
The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of protein kinases, and methods for their use in treating disorders mediated, at least in part by, protein kinases.  
WO/2021/057009A1
The present invention provides an improved N-heterocyclic planar optical coupling output material. The general structural formula of the N-heterocyclic planar optical coupling output material is R1-R2-R1. The structural formula of the sy...  
WO/2021/061204A1
The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions. In some embodiments, the compounds disclos...  
WO/2021/061642A1
The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions. In some embodiments, the compounds disclos...  
WO/2021/060949A1
The present invention relates to a co-crystalline efinaconazole, and a method for producing same, wherein an efinaconazole and a pharmaceutically acceptable co-former are formed as a co-crystal. An efinaconazole co-crystallized product a...  
WO/2021/057550A1
The present invention provides an organic compound and an electronic device containing the organic compound, which belongs to the technical field of organic materials. The structure of the organic compound is as shown in chemical formula...  
WO/2021/058759A1
The present invention relates to an organic semiconductor layer and an organic electronic device comprising the same, wherein the organic electronic device comprises an anode, a cathode and at least one organic semiconductor layer, where...  
WO/2021/057264A1
The present disclosure relates to the technical field of organic materials, and provides a compound as represented by formula (I), a photoelectric conversion device, and an electronic device. The compound can reduce the working voltage o...  
WO/2021/060950A1
The present invention relates to an amorphous efinaconazole solid dispersion, and a method for preparing same, the solid dispersion comprising efinaconazole in amorphous form, and one or more stabilizing carriers selected from hydroxypro...  
WO/2021/057813A1
Disclosed are a sulfimide photo-acid generator, a photosensitive resin composition, a patterning method, and a use of the photosensitive resin composition. The photosensitive resin composition comprises a resin component and an acid gene...  
WO/2021/057975A1
A compound (as shown in formula I) as a mutant isocitrate dehydrogenase 2 (IDH2) inhibitor, and a preparation method and a pharmaceutical composition thereof. Also disclosed is a use of the compound or pharmaceutical composition thereof ...  

Matches 101 - 150 out of 67,048